

Daniel Ontaneda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3754821/publications.pdf>

Version: 2024-02-01

90
papers

2,902
citations

218677

26
h-index

182427

51
g-index

91
all docs

91
docs citations

91
times ranked

4214
citing authors

#	ARTICLE	IF	CITATIONS
1	Decentralised clinical trials in multiple sclerosis research. <i>Multiple Sclerosis Journal</i> , 2023, 29, 317-325.	3.0	2
2	Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI. <i>Multiple Sclerosis Journal</i> , 2022, 28, 198-205.	3.0	18
3	T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis—yes. <i>Multiple Sclerosis Journal</i> , 2022, 28, 352-354.	3.0	6
4	New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure. <i>Journal of Neuroimmunology</i> , 2022, 362, 577785.	2.3	34
5	Slowly Expanding Lesions. <i>Neurology</i> , 2022, 98, 699-700.	1.1	4
6	Association of socioeconomic disadvantage and neighborhood disparities with clinical outcomes in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103734.	2.0	6
7	Visual imaging as a predictor of neurodegeneration in experimental autoimmune demyelination and multiple sclerosis. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	5.2	5
8	Pembrolizumab-Induced CNS Vasculitis. <i>Neurology: Clinical Practice</i> , 2021, 11, e30-e32.	1.6	4
9	Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102635.	2.0	7
10	Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. <i>NeuroImage: Clinical</i> , 2021, 32, 102834.	2.7	23
11	Juxtacortical susceptibility changes in progressive multifocal leukoencephalopathy at the grayâ€“white matter junction correlates with iron-enriched macrophages. <i>Multiple Sclerosis Journal</i> , 2021, 27, 135245852199965.	3.0	5
12	Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement. <i>Brain</i> , 2021, 144, 1974-1984.	7.6	31
13	Predicting disability worsening in relapsing and progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2021, 34, 312-321.	3.6	9
14	Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e881-e889.	1.1	30
15	Integrating patient-reported outcomes and quantitative timed tasks to identify relapsing remitting multiple sclerosis patient subgroups: a latent profile analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102912.	2.0	1
16	Novel de novo TREX1 mutation in a patient with retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations mimicking demyelinating disease. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103015.	2.0	4
17	Is computerized screening for processing speed impairment sufficient for identifying MS-related cognitive impairment in a clinical setting?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103106.	2.0	4
18	Prediction in treatment outcomes in multiple sclerosis: challenges and recent advances. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1187-1198.	3.0	0

#	ARTICLE	IF	CITATIONS
19	MRI, Big Data, and Artificial Intelligence. <i>Neurology</i> , 2021, 97, 975-976.	1.1	0
20	Vitamin D Levels and Visual System Measurements in Progressive Multiple Sclerosis. <i>International Journal of MS Care</i> , 2021, 23, 53-58.	1.0	5
21	MOG-related disorders: A new cause of imaging-negative myelitis?. <i>Multiple Sclerosis Journal</i> , 2020, 26, 511-515.	3.0	15
22	Clinical observation during alemtuzumab administration. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101412.	2.0	1
23	Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder. <i>Neurology</i> , 2020, 94, 273-275.	1.1	6
24	Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101525.	2.0	11
25	Fourteen-year serial MRIs of patients with mild and severe courses of MS. <i>Neurology: Clinical Practice</i> , 2020, 10, e5-e6.	1.6	1
26	Multiple sclerosis management during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1163-1171.	3.0	63
27	Comorbidity effect on processing speed test and MRI measures in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102593.	2.0	6
28	Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy. <i>Journal of Neuroimaging</i> , 2020, 30, 251-266.	2.0	24
29	Keep the Worms in the Mud. <i>JAMA Neurology</i> , 2020, 77, 1066.	9.0	3
30	Technology-enabled assessments to enhance multiple sclerosis clinical care and research. <i>Neurology: Clinical Practice</i> , 2020, 10, 222-231.	1.6	12
31	Detection of central vein should be part of MS diagnostic criteria – Yes. <i>Multiple Sclerosis Journal</i> , 2020, 26, 405-406.	3.0	1
32	Achieving effective patient and public involvement in international clinical trials in neurology. <i>Neurology: Clinical Practice</i> , 2020, 10, 265-272.	1.6	1
33	Controversial association between leptomeningeal enhancement and demyelinated cortical lesions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 135-136.	3.0	11
34	Cognitive processing speed in multiple sclerosis clinical practice: association with patient-reported outcomes, employment and magnetic resonance imaging metrics. <i>European Journal of Neurology</i> , 2020, 27, 1238-1249.	3.3	26
35	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. <i>Contemporary Clinical Trials</i> , 2020, 95, 106009.	1.8	31
36	Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 88, 81-92.	5.3	33

#	ARTICLE	IF	CITATIONS
37	Thalamic Injury and Cognition in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 623914.	2.4	28
38	Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. <i>Lancet Neurology</i> , The, 2019, 18, 973-980.	10.2	99
39	Diagnosis and Management of Progressive Multiple Sclerosis. <i>Biomedicines</i> , 2019, 7, 56.	3.2	53
40	Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116498.	0.6	14
41	Prevalence of multiple sclerosis in Cuenca, Ecuador. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731988495.	1.0	0
42	Pragmatic clinical trials for treating relapsing multiple sclerosis. <i>Lancet Neurology</i> , The, 2019, 18, 1075.	10.2	2
43	Vitamin D and MRI measures in progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 276-282.	2.0	11
44	Comprehensive Autopsy Program for Individuals with Multiple Sclerosis. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	12
45	Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731987546.	1.0	8
46	Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731985603.	1.0	8
47	Imaging outcome measures of neuroprotection and repair in MS. <i>Neurology</i> , 2019, 92, 519-533.	1.1	53
48	MS progression is predominantly driven by age-related mechanisms “ NO. <i>Multiple Sclerosis Journal</i> , 2019, 25, 904-906.	3.0	6
49	Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731988719.	1.0	7
50	Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731989174.	1.0	7
51	Multiple sclerosis risk factors contribute to onset heterogeneity. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 11-16.	2.0	36
52	Clinical commentary on “Warts and all: Fingolimod and unusual HPV associated lesions”. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1550-1552.	3.0	4
53	Progressive Multiple Sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 736-752.	0.8	15
54	Stem cell injection-induced glioneuronal lesion of the cauda equina. <i>Neurology</i> , 2018, 90, 613-615.	1.1	3

#	ARTICLE	IF	CITATIONS
55	Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm. <i>Multiple Sclerosis Journal</i> , 2018, 24, 750-757.	3.0	50
56	Treatment decisions in MS: Shifting the goal posts or changing how we see them?. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1523-1525.	3.0	1
57	Identifying a new subtype of multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 2018, 8, 367-369.	2.2	3
58	Automated Integration of Multimodal MRI for the Probabilistic Detection of the Central Vein Sign in White Matter Lesions. <i>American Journal of Neuroradiology</i> , 2018, 39, 1806-1813.	2.4	29
59	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018, 379, 846-855.	27.0	201
60	Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. <i>Neurology: Clinical Practice</i> , 2018, 8, 292-301.	1.6	25
61	Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. <i>Lancet Neurology</i> , The, 2018, 17, 870-884.	10.2	103
62	The challenges and opportunities of multiple sclerosis care in Latin America. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731772084.	1.0	0
63	Clinical outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1627-1635.	3.0	32
64	T1&T2-weighted ratio differs in demyelinated cortex in multiple sclerosis. <i>Annals of Neurology</i> , 2017, 82, 635-639.	5.3	82
65	The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials. <i>Neurotherapeutics</i> , 2017, 14, 905-923.	4.4	23
66	Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS – Commentary. <i>Multiple Sclerosis Journal</i> , 2017, 23, 508-509.	3.0	3
67	Imaging as an Outcome Measure in Multiple Sclerosis. <i>Neurotherapeutics</i> , 2017, 14, 24-34.	4.4	50
68	Measuring Brain Tissue Integrity during 4 Years Using Diffusion Tensor Imaging. <i>American Journal of Neuroradiology</i> , 2017, 38, 31-38.	2.4	20
69	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. <i>Lancet</i> , The, 2017, 389, 1357-1366.	13.7	235
70	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017, 140, 2776-2796.	7.6	139
71	Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2017, Volume 7, 31-45.	1.3	5
72	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 44-52.	2.0	43

#	ARTICLE	IF	CITATIONS
73	Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. <i>Contemporary Clinical Trials</i> , 2016, 50, 166-177.	1.8	59
74	The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. <i>Nature Reviews Neurology</i> , 2016, 12, 714-722.	10.1	274
75	Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 8, 124-130.	2.0	37
76	Propensity methods for multiple sclerosis: The devil is in the details. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1248-1249.	3.0	0
77	Progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2015, 28, 237-243.	3.6	65
78	Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. <i>Lancet Neurology</i> , The, 2015, 14, 208-223.	10.2	188
79	Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis. <i>CNS Drugs</i> , 2015, 29, 759-771.	5.9	16
80	Camptocormia and Pisa syndrome as manifestations of acute myasthenia gravis exacerbation. <i>Journal of the Neurological Sciences</i> , 2015, 359, 8-10.	0.6	7
81	Experience with fingolimod in clinical practice. <i>International Journal of Neuroscience</i> , 2015, 125, 678-685.	1.6	31
82	Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?. <i>International Journal of Neuroscience</i> , 2014, 124, 509-511.	1.6	43
83	Diffusion tensor imaging before, during and after progressive multifocal leukoencephalopathy. <i>European Journal of Neurology</i> , 2014, 21, e36-8.	3.3	1
84	Identifying the Start of Multiple Sclerosis Injury: A Serial DTI Study. <i>Journal of Neuroimaging</i> , 2014, 24, 569-576.	2.0	21
85	The benefits and risks of alemtuzumab in multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 189-191.	3.0	4
86	Multiple Sclerosis Treatment. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013, 19, 1092-1099.	0.8	1
87	Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1074-1080.	3.0	67
88	Early tolerability and safety of fingolimod in clinical practice. <i>Journal of the Neurological Sciences</i> , 2012, 323, 167-172.	0.6	44
89	Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics. <i>Annual Review of Medicine</i> , 2012, 63, 389-404.	12.2	64
90	Measuring Myelin Repair and Axonal Loss with Diffusion Tensor Imaging. <i>American Journal of Neuroradiology</i> , 2011, 32, 85-91.	2.4	127